Clario joins Avoca Quality Consortium
Technology company expands membership with The Avoca Group, helping to define and improve clinical trial quality
- Clario joins The Avoca Group’s Avoca Quality Consortium (AQC), a collaborative that aims to achieve better quality in clinical trials
- Dr. Otis Johnson, Ph.D., M.P.A., Clario’s Chief Diversity, Inclusion and Sustainability Officer, spoke at the WCG Avoca Quality and Innovation Summit’s Executive Panel on May 26
PHILADELPHIA, PA — May 27, 2022 — Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced it has expanded its membership with The Avoca Group by joining its Avoca Quality Consortium (AQC). AQC is a collaborative that unites key industry stakeholders with the shared goal of elevating quality in clinical trials. As a member of AQC, Clario will work with sponsors and Contract Research Organizations, to continue to define and improve clinical trial quality.
“This is a huge opportunity for us to advance the level of quality in clinical trials,” said Chief Strategy and Marketing Officer, Matt McCarty. “We look forward to contributing our expertise while also learning from other member companies. Together, we can navigate industry challenges to deliver better quality solutions for partners and patients.”
The WCG Avoca Quality & Innovation Summit is the premier event that Avoca produces annually. This year, Dr. Johnson participated in a panel discussion with senior executives from Merck, Astellas, Eli Lilly and Amgen on Thursday, May 26.
“This session presented an opportunity for a conversation about how we as an industry define quality in clinical trials,” said Dr. Johnson. “Today, quality and trust must go hand in hand. This means, for example, we must consider the role that diversity and inclusion (D&I) plays in increasing trust in clinical trials. Testing a treatment on a diverse participant population is essential to achieving true quality data that can be trusted.”
To learn more about the Avoca Quality Consortium, visit their website.
Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale, and the broadest endpoint technology platform in the industry, allows our partners to transform lives. Clario’s solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving the patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.
Clario Media Contact
Sr. Director, PR and Thought Leadership